More than 17,000 medicinal cannabis prescriptions were approved by the health regulator in February, the fourth highest on record.
It takes the two-month 2025 total of Special Access Scheme approvals to 33,520, 47% higher than the same period last year and 82% up on 2023.
Applications were submitted to the Therapeutic Goods Administration (TGA) by 911 prescribers, 56 more than January.
THC-dominant products were again the most prescribed by doctors during February, responsible for 52% of the applications rubber-stamped by the TGA, down from 52% the previous month.
Category 3 medicine – a balance of THC and CBD – and CBD-dominant category 1 products both took 17%.
Flower maintained top spot as the most-prescribed dosage form through the SAS, capturing almost 40% of the 17,306 approvals, down from 42% in January.
Oral solutions represented 36% of approvals, up from 33.5%, while pastilles, which have seen a rapid rise in recent months, remained steady on 14%.
In line with historical trends, chronic pain was the condition for which medicinal cannabis was most prescribed, generating close to 42% of approvals, followed by anxiety (33%), sleep disorders (14%) and Post Traumatic Stress Disorder (2%).
The state-by-state data showed doctors in Victoria continue to generate the greatest number of successful applications, with 45% of approvals.
Queensland took 35%, New South Wales 15% and Western Australian was a distant fourth with less than 2%.
